Recursion Pharmaceuticals (RXRX) EBT (2020 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly EBT came in at -$122.1 million in Q1 2026, up 39.74% YoY from -$87.4 million in Q1 2025, and down 12.96% on a QoQ basis from -$108.1 million in Q4 2025.
Recursion Pharmaceuticals (RXRX) EBT (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 7 years of EBT data on file, last reported at -$122.1 million in Q1 2026.
- Quarterly EBT rose 39.74% year-over-year to -$122.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$564.4 million (up 1.9% YoY) and the FY2025 annual result came in at -$644.9 million, down 38.75% from the prior year.
- EBT retreated to -$122.1 million in Q1 2026, from -$108.1 million in the prior quarter.
- In the past five years, EBT ranged from a high of -$56.0 million in Q1 2022 to a low of -$202.6 million in Q1 2025.
- A 5-year average of -$106.9 million and a median of -$95.7 million in 2024 frame the typical range for EBT.
- Annual changes were most pronounced in 2025 — EBT tumbled 119.9% — and 2026, when it soared 39.74%.
- Tracing RXRX's EBT over 5 years: stood at -$68.0 million in 2022, then slumped by 42.63% to -$97.1 million in 2023, then slumped by 84.32% to -$178.9 million in 2024, then surged by 39.57% to -$108.1 million in 2025, then dropped by 12.96% to -$122.1 million in 2026.
- The last three EBT figures came in at -$122.1 million (Q1 2026), -$108.1 million (Q4 2025), and -$162.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | -131.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -131.01 Mn |
| Mar 31, 2026 | -122.11 Mn |
| Dec 31, 2025 | -108.10 Mn |
| Sep 30, 2025 | -162.25 Mn |
| Jun 30, 2025 | -171.90 Mn |
| Mar 31, 2025 | -202.65 Mn |
| Dec 31, 2024 | -178.90 Mn |
| Sep 30, 2024 | -95.68 Mn |
| Jun 30, 2024 | -98.06 Mn |
| Mar 31, 2024 | -92.15 Mn |
| Dec 31, 2023 | -97.06 Mn |
| Sep 30, 2023 | -93.02 Mn |
| Jun 30, 2023 | -76.73 Mn |
| Mar 31, 2023 | -65.33 Mn |
| Dec 31, 2022 | -68.05 Mn |
| Sep 30, 2022 | -62.59 Mn |
| Jun 30, 2022 | -66.21 Mn |
| Mar 31, 2022 | -56.00 Mn |
| Dec 31, 2021 | -64.98 Mn |
| Sep 30, 2021 | -46.62 Mn |